{"id":"https://openalex.org/W2016379765","doi":"https://doi.org/10.1002/cncr.23606","title":"Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: A phase 2 trial of the Minnie Pearl Cancer Research Network","display_name":"Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: A phase 2 trial of the Minnie Pearl Cancer Research Network","alternate_titles":[],"publication_year":2008,"publication_date":"2008-06-09","ids":{"openalex":"https://openalex.org/W2016379765","doi":"https://doi.org/10.1002/cncr.23606","mag":"2016379765","pmid":"https://pubmed.ncbi.nlm.nih.gov/18543319"},"language":"en","primary_location":{"id":"doi:10.1002/cncr.23606","doi":"https://doi.org/10.1002/cncr.23606","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.23606","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23606","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2016379765"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23606","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"John D. Hainsworth","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA. jhainsworth@tnonc.com","Sarah Cannon Research Institute, Nashville, Tennessee","Tennessee Oncology, PLLC, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA. jhainsworth@tnonc.com","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"Tennessee Oncology, PLLC, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018054038","display_name":"David Robert Spigel","orcid":"https://orcid.org/0000-0003-3215-9465","observed_orcids":["https://orcid.org/0000-0003-3215-9465"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David R. Spigel","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tennessee","Tennessee Oncology, PLLC, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"Tennessee Oncology, PLLC, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084628101","display_name":"John H. Barton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Barton","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044246734","display_name":"Cindy P. Farley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cindy Farley","raw_affiliation_strings":["see","Tennessee Oncology, PLLC, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"see","institution_ids":[]},{"raw_affiliation_string":"Tennessee Oncology, PLLC, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025465348","display_name":"Marshall T. Schreeder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118515","display_name":"Clearview Cancer Institute","ror":"https://ror.org/020cs7q41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210118515"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marshall Schreeder","raw_affiliation_strings":["Clearview Cancer Institute, Huntsville, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clearview Cancer Institute, Huntsville, Alabama","institution_ids":["https://openalex.org/I4210118515"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086481226","display_name":"Jeremy K. Hon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118515","display_name":"Clearview Cancer Institute","ror":"https://ror.org/020cs7q41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210118515"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy Hon","raw_affiliation_strings":["Clearview Cancer Institute, Huntsville, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clearview Cancer Institute, Huntsville, Alabama","institution_ids":["https://openalex.org/I4210118515"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073724595","display_name":"F. Anthony Greco","orcid":"https://orcid.org/0009-0009-4578-0630","observed_orcids":["https://orcid.org/0009-0009-4578-0630"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Anthony Greco","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5065917441"],"corresponding_institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":null,"fwci":2.0121,"has_fulltext":true,"cited_by_count":35,"citation_normalized_percentile":{"value":0.8624206,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"113","issue":"4","first_page":"765","last_page":"771"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.996999979019165},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8880000114440918},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.9639999866485596},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8050000071525574},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.7720000147819519},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6980000138282776},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8820000290870667},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8510000109672546},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.847000002861023},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9010000228881836},{"id":"https://openalex.org/keywords/neuropathy","display_name":"neuropathy","score":0.8029999732971191}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9382756948471069},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9155828952789307},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7914775609970093},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7302682399749756},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6171873211860657},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5523048639297485},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.49840521812438965},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.423258513212204},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3215349316596985},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.321230411529541},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cncr.23606","doi":"https://doi.org/10.1002/cncr.23606","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.23606","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23606","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},{"id":"pmid:18543319","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18543319","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1002/cncr.23606","doi":"https://doi.org/10.1002/cncr.23606","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.23606","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23606","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2016379765.pdf","grobid_xml":"https://content.openalex.org/works/W2016379765.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W1979300931","https://openalex.org/W2021242983","https://openalex.org/W2044436186","https://openalex.org/W2097007321","https://openalex.org/W2100608938","https://openalex.org/W2108235071","https://openalex.org/W2111650326","https://openalex.org/W2120590293","https://openalex.org/W2122684890","https://openalex.org/W2124560610","https://openalex.org/W2129228847","https://openalex.org/W2138077682","https://openalex.org/W2156748957","https://openalex.org/W2254963616","https://openalex.org/W2341286942","https://openalex.org/W2497744464","https://openalex.org/W2554908277","https://openalex.org/W2563483539","https://openalex.org/W2570495056","https://openalex.org/W2574432882","https://openalex.org/W2593469829","https://openalex.org/W3041047318","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2248132431","https://openalex.org/W2980555685","https://openalex.org/W2097007321","https://openalex.org/W2569232645","https://openalex.org/W2522241980","https://openalex.org/W2165897928","https://openalex.org/W3031833561","https://openalex.org/W2073185898","https://openalex.org/W2352427406","https://openalex.org/W2559005997"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,96,114],"purpose":[2],"of":[3,14,20,29,52,93,112,160,169,204,215,223],"the":[4,10,18,135,164,188,201,213],"current":[5,165],"study":[6],"was":[7,103,128,172],"to":[8,86,174,195],"evaluate":[9],"efficacy":[11,203],"and":[12,116,123,152,177,191,239],"toxicity":[13],"weekly":[15,170,221],"bortezomib":[16,48,127,171,224],"in":[17,180],"treatment":[19,43],"patients":[21,31,77,102,181,230],"with":[22,32,47,88,106,182,198],"recurrent/refractory":[23],"multiple":[24,33,185],"myeloma.":[25,186],"METHODS:":[26],"A":[27,220],"total":[28],"40":[30],"myeloma":[34],"who":[35,231],"had":[36],"received":[37],"either":[38],"1":[39,62],"or":[40],"2":[41,206,218],"previous":[42],"regimens":[44],"were":[45,67,121,155],"treated":[46,184],"at":[49],"a":[50,89,107,158,167,226,236],"dose":[51],"1.6":[53],"mg/m(2)":[54],"intravenously":[55],"for":[56,100,229,244],"4":[57],"consecutive":[58],"weeks,":[59],"followed":[60],"by":[61,157],"week":[63],"without":[64],"treatment.":[65],"Responses":[66],"measured":[68],"using":[69],"International":[70],"Myeloma":[71],"Working":[72],"Group":[73],"criteria.":[74],"RESULTS:":[75],"Twenty-two":[76],"(55%;":[78],"95%":[79],"confidence":[80],"interval,":[81],"40%-70%)":[82],"achieved":[83,197],"objective":[84],"responses":[85],"treatment,":[87],"median":[90,97],"response":[91,189],"duration":[92,192],"16":[94],"months.":[95],"progression-free":[98,109],"survival":[99,110,119],"all":[101],"9.6":[104],"months,":[105],"1-year":[108,115],"rate":[111,190],"39%.":[113],"2-year":[117],"overall":[118],"rates":[120],"75%":[122],"51%,":[124],"respectively.":[125],"Weekly":[126],"generally":[129],"well":[130,178],"tolerated;":[131],"grade":[132],"3/4":[133],"(using":[134],"National":[136],"Cancer":[137],"Institute":[138],"Common":[139],"Toxicity":[140],"Criteria":[141],"[version":[142],"3.0])":[143],"neutropenia":[144],"(13%),":[145,151],"thrombocytopenia":[146],"(20%),":[147],"fatigue":[148],"(15%),":[149],"diarrhea":[150],"neuropathy":[153],"(10%)":[154],"experienced":[156],"minority":[159],"patients.":[161],"CONCLUSIONS:":[162],"In":[163],"study,":[166],"schedule":[168,222,243],"found":[173],"be":[175,209],"effective":[176],"tolerated":[179],"previously":[183],"Although":[187],"appear":[193],"comparable":[194],"those":[196],"twice-weekly":[199,237],"bortezomib,":[200],"relative":[202],"these":[205],"schedules":[207],"cannot":[208],"determined":[210],"definitively":[211],"on":[212],"basis":[214],"this":[216],"phase":[217],"study.":[219],"is":[225,240],"reasonable":[227],"option":[228],"have":[232],"logistic":[233],"difficulties":[234],"receiving":[235],"schedule,":[238],"an":[241],"attractive":[242],"incorporation":[245],"into":[246],"combination":[247],"regimens.":[248]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2016379765","counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
